Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 5/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | PPARD | Q03181 | 5/20 | 0.38 |
| ▸ | PPARA | Q07869 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25778964 | 1.00 | OXER1 (0.42) | OXER1RXFP1PPARGPPARDPPARA | |
| SCHEMBL287263 | 0.87 | OXER1 (0.54) | OXER1 | |
| SCHEMBL3699735 | 0.87 | OXER1 (0.54) | OXER1 | |
| SCHEMBL25777910 | 0.85 | OXER1 (0.45) | OXER1RXFP1PPARGPPARDPPARA | |
| SCHEMBL18113212 | 0.85 | OXER1 (0.45) | OXER1RXFP1PPARGPPARDPPARA | |
| SCHEMBL20014473 | 0.83 | OXER1 (0.47) | OXER1RXFP1PPARGPPARDPPARA | |
| SCHEMBL18112910 | 0.83 | OXER1 (0.49) | OXER1PPARGPPARDPPARAMEN1 | |
| SCHEMBL18126615 | 0.82 | OXER1 (0.41) | OXER1PPARGPPARDPPARAMEN1 | |
| SCHEMBL10116432 | 0.81 | OXER1 (0.44) | OXER1RXFP1PPARGPPARDPPARA | |
| SCHEMBL25777909 | 0.81 | PPARG (0.56) | OXER1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107635961-B | Indole analogs as 5-oxo-ETE receptor antagonists and methods of use thereof | 皇家学习促进学会/麦吉尔大学 | 2021-07-20 | — | — | CN | disclosed |
| EP-3277665-B1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2020-03-04 | — | — | EP | disclosed |
| EP-3277665-B1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2020-03-04 | — | — | EP | disclosed |
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-03-29 | — | — | US | disclosed |
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-03-29 | — | — | US | disclosed |
| EP-3277665-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016154749-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016154749-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | HTR5A, EDNRA, HTR3E | OXER1 27/4885RXFP1 219/4885PPARG 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.